Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 30 of 30 publications.

Raza S, Heyes A, Leonard C, D'Souza V, Carney R, Mackie D, Gelinas D, Swijsen A. Analysis of the burden of illness, treatment, and health disparities in amyotrophic lateral sclerosis. Poster to be given at the ISPOR 2025; May 15, 2025. Montréal, Canada.

Hellwig K, Magyari M, MacDonald TM, Cesta CE, Wergeland S, Leinonen MK, Ornoy A, Vukusic S, Lauer A, Zhou X, Kawai A, Weinrib R, Arana A, Boumenna T. A multi-country cohort database study to assess pregnancy and infant outcomes after potential maternal or paternal exposure to cladribine tablets in the treatment of multiple sclerosis: the CLEAR study methods and status update1. Ther Adv Neurol Disord. 2025 Jan 27;18:175628642. doi: 10.1177/17562864241310996

Halsby K, Gildea L, Madhava H, Angulo FJ, Pilz A, Erber W, Moisi J, Schley K, Colosia A, Sellner J. Clinical manifestations and outcomes of tick-borne encephalitis: a systematic literature review. Ticks Tick Borne Dis. 2024 Nov 4;15(6):102407. doi: 10.1016/j.ttbdis.2024.102407

Bagnato F, Mordin M, Greene N, Mahida S, Higuchi K, van Wingerden J. Evaluating association of chronic active lesions with disability in multiple sclerosis: a systematic literature review. Poster presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2024; October 14, 2024. Las Vegas, NV. [abstract] J Manag Care Spec Pharm. 2024 Oct; 30(10-c):S155. Previously presented at the 10th Congress of the European Academy of Neurology.

Bagnato F, Mordin M, Greene N, Mahida S, Higuchi K, Wingerden J. Evaluating association of chronic active lesions with disability in multiple sclerosis: a systematic literature review. Poster presented at the 10th Congress of the European Academy of Neurology; June 29, 2024. Helenski, Finland. [abstract] Eur J Neurol. 2024 Jun; 31(Suppl 1).

Blumenfeld A, Mordin M, Kosa K, Castro C, Stokes J, Shah D, Buse DC. Exploring the experience of neck pain in individuals with episodic migraine. Poster presented at the International Neurotoxin Association 7th International Conference (TOXINS 2024); January 17, 2024. Barcelona, Spain. Previously presented at the American Academy of Neurology (AAN) 2023 Annual Meeting.

Halsby K, Gildea L, Colosia A, Madhava H, Erber W, Angulo F, Pilz A, Schley K, Moisi J, Sellner J. The clinical spectrum of TBE infections in adult and paediatric populations in Europe: a systematic review. Poster presented at the International Symposium on Tick-Borne Pathogens and Disease (ITPD) 2023; October 24, 2023. Vienna, Austria.

Blumenfeld AM, Mordin M, Kosa KM, Castro CV, Stokes J, Shah D, Buse DC. Exploring the experience of neck pain in individuals with episodic migraine. Poster presented at the American Academy of Neurology (AAN) 2023 Annual Meeting; April 23, 2023. Boston, MA.

Copley-Merriman C, D'Souza V, Arvin-Berod C, Phillips G, Verheesen P, Heyerick A, Stoykov I. Evidence gap analysis of the burden of illness and treatment of pemphigus vulgaris and foliaceus. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S41. doi: 10.1016/j.jval.2022.09.198

Fernandez M, Copley-Merriman C, Arvin-Berod C, Phillips G, Gelinas D, Weiss R, Hofman E, Tse A. Evidence gap analysis of the burden of illness and treatment of chronic inflammatory demyelinating polyneuropathy. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S34. doi: 10.1016/j.jval.2022.09.164

Yang J, Masaquel C, Arvin-Berod C, Phillips G, Godar M, Desai M, Ayguasanosa J. Evidence gap analysis of the burden of illness and treatment of primary immune thrombocytopenia. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S19. doi: 10.1016/j.jval.2022.09.094

Copley-Merriman C, Yang X, Juniper M, Amin S, Yoo HK, Sen SS. Natural history and disease burden of neurofibromatosis type 1 with plexiform neurofibromas: a systematic review. Adolesc Health Med Ther. 2021 May 19;12:55-66. doi: 10.2147/AHMT.S303456

Hartry A, Menne H, Wronski S, Paulson R, Callahan L, Potashman M, Lee D, Wunderlich G, Hoffman D, Wieberg D, Kremer I, Hauber B, DiBenedetti D. Evaluation of what matters most in existing clinical outcomes assessments in Alzheimer's Disease. Poster presented at the 2020 Alzheimer's Association Virtual International Conference (AAIC); July 29, 2020.

Copley-Merriman C, Yang X, Juniper M, Amin S, Yoo HK, Sen S. Impact of neurofibromatosis type 1 and plexiform neurofibromas on patient-reported health-related quality of life. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S344. doi: 10.1016/j.jval.2020.04.371

Costello J, Njue A, Lyall M, Heyes A, Mahler N, Philbin M, Nazareth T. Efficacy, safety, and quality-of-life of treatments for acute relapses of multiple sclerosis: results from a literature review of randomized controlled trials. Degener Neurol Neuromuscul Dis. 2019 Jul 1;9:55-78. doi: 10.2147/DNND.S208815

Drahos J, Evans E, Stevenson A, Heyes A, Hoffman D. A comprehensive burden-of-illness review for Type 1 and Type 2 narcolepsy. Poster presented at the 7th International Narcolepsy Symposium 2018; September 9, 2018. Beverly, MA.

Matharu M, Pascual J, Nisson Remahl I, Straube A, Lum A, Davar G, Odom D, Bennett L, Proctor C, Gutierrez L, Andrews E, Johannes C. Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe. Cephalalgia. 2017 Dec;37(14):1384-97. doi: 10.1177/0333102417724150

Luciano JV, D’Amico F, Feliu-Soler A, McCracken LM, Aguado J, Penarrubia-Maria MT, Knapp M, Serrano-Blanco A, Garcia-Campayo J. Cost-utility of group acceptance and commitment therapy for fibromyalgia versus recommended drugs: an economic analysis alongside a 6-month randomized controlled trial conducted in Spain (EFFIGACT Study). J Pain. 2017 Jul;18(7):868-80. doi: 10.1016/j.jpain.2017.03.001

Tell-Marti G, Puig-Butille JA, Potrony M, Plana E, Badenas C, Antonell A, Sanchez-Valle R, Molinuevo JL, Lleo A, Alcolea D, Fortea J, Fernandez-Santiago R, Clarimon J, Llado A, Puig S. A common variant in the MC1R gene (p.V92M) is associated with Alzheimer's disease risk. J Alzheimers Dis. 2017 Feb 3;56(3):1065-74. doi: 10.3233/JAD-161113

Alamo-Junquera D, Sunyer J, Iniguez C, Ballester F, Garcia-Esteban R, Forns J, Turner MC, Lertxundi A, Lertxundi N, Fernandez-Somoano A, Rodriquez-Dehli C, Julvez J. Prenatal head growth and child neuropsychological development at age 14 months. Am J Obstet Gynecol. 2015 May;212(5):661e1-e11. doi: 10.1016/j.ajog.2014.12.001

Mordin M, Masaquel C, Abbott C, Copley-Merriman C. Factors affecting the health-related quality of life of patients with cervical dystonia and impact of treatment with abobotulinumtoxinA (Dysport): results from a randomised, double-blind, placebo-controlled study. BMJ Open. 2014 Oct 16;4(10):e005150. doi: 10.1136/bmjopen-2014-005150

Matharu M, Pascual J, Nilsson Remahl I, Odom D, Gutierrez L, Andrews E, Largent J, Johannes C. EHMTI-0192. Onabotulinumtoxina prophylaxis in chronic migraine utilization and patient characteristics: observational study in the European Union. Poster presented at the 4th European Headache and Migraine Trust International Congress 2014; September 2014. Copenhagen, Denmark. [abstract] J. Headache Pain. 2014 Sep 18; 15(Suppl 1):G24. doi: 10.1186/1129-2377-15-S1-G24

Luciano JV, Barrada JR, Aguado J, Osma J, García-Campayo J. Bifactor analysis and construct validity of the HADS: a cross-sectional and longitudinal study in fibromyalgia patients. Psychological Assessment. 2014 Jun;26(2):395-406.

Luciano JV, Guallar JA, Aguado J, López-Del-Hoyo Y, Olivan B, Magallón R, Alda M, Serrano-Blanco A, Gili M, García-Campayo J. Effectiveness of group acceptance and commitment therapy for fibromyalgia: a 6-month randomized controlled trial (EFFIGACT study). Pain. 2014 Apr;155(4):693-702.

Luciano JV, Aguado J, Serrano-Blanco A, Calandre EP, Rodriguez-Lopez CM. Dimensionality, reliability, and validity of the revised fibromyalgia impact questionnaire in two Spanish samples. Arthritis Care Res (Hoboken). 2013 Oct;65(10):1682-9.

Juniper MD, McCrink L, Mladsi DM, Le TK. The burden of fibromyalgia in France, Germany, Italy, Spain, and the UK: a literature-based review. Poster presented at the Annual Congress of the European League Against Rheumatism; June 2008. Paris, France.

Gaffney L, Sherrill EH, Wolowacz SE, Allen R, Connolly M. Predictors of health-related quality of life (HRQoL) in US patients suffering from rls. Poster presented at the International Congress on Parkinson's Disease and Movement Disorders; 2005.

Barrows SM, Brown MT. Effect of valdecoxib on functional impairment, quality of life and patient satisfaction in migraine patients. Poster presented at the Annual Meeting of the American College of Nurse Practitioners; October 2004.

Rowland CR, Barrows SM, Brown MT. Effects of valdecoxib on functional impairment, quality of life and treatment satisfaction in migraine patients. Poster presented at the Annual Meeting of the International Headache Society; September 2003.

Duff SB, Mordin MM. Strategies for assessing health economic and quality-of-life outcomes in multiple sclerosis. Expert Rev Pharmacoecon Outcomes Res. 2002 Dec;2(6):577-87.